Imprimis Pharmaceuticals Inc (IMMY)

[ireadthefins]

Technically, yes you are right the company did report positive EPS (.11 diluted) in Q218. I was implying the company still isn't profitable from regular operations (sales revenue-cost to produce-cost to sell and maintain day to day operations), not including 'other income', which isn't recurring or part of normal business. Gains from the deconsolidation of the subsidiaries (Eton and, specifically Surface) recorded in other income are what boosted net income to positive in Q217 and Q218. A sustainable businesses strategy isn't to be an incubation machine for subsidiary spin-offs. In order to grow and become profitable, the company will have to increase sales and improve operating efficiency. I'm just wondering what the plan is to accomplish this?